Abstract Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2), is a new human disease with few effective …

Importance Convalescent plasma is a potential therapeutic option for patients with
coronavirus disease 2019 (COVID-19), but further data from randomized clinical trials are …

As more and more patients recover from coronavirus disease 2019 (COVID-19) in the
coming weeks, convalescent plasma will become increasingly accessible as a treatment …

Background Polyclonal convalescent plasma may be obtained from donors who have
recovered from coronavirus disease 2019 (Covid-19). The efficacy of this plasma in …

In a randomized clinical trial of 86 hospitalized COVID-19 patients comparing standard care
to treatment with 300mL convalescent plasma containing high titers of neutralizing SARS …

Background There is currently no treatment known to alter the course of coronavirus disease
2019 (COVID-19). Convalescent plasma has been used to treat a number of infections …

BACKGROUND Although convalescent plasma has been widely used to treat severe
coronavirus disease 2019 (COVID-19), data from randomized controlled trials that support …

Importance Patients who are immunocompromised have increased risk for morbidity and
mortality associated with coronavirus disease 2019 (COVID-19) because they less …

To determine the effect of COVID-19 convalescent plasma on mortality, we aggregated
patient outcome data from 10 randomized clinical trials, 20 matched control studies, 2 dose …

Convalescent plasma has been used worldwide to treat patients hospitalized with
coronavirus disease 2019 (COVID-19) and prevent disease progression. Despite global …